CCM
DGX icon

Chimera Capital Management’s Quest Diagnostics DGX Stock Holding History

Chimera Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,480
Closed -$791K – 213
2022
Q3 		$791K Buy
+6,480
New +$853K 0.22% 103

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chimera Capital Management's DGX Position: Q4 2022 in Review

Chimera Capital Management sold out of Quest Diagnostics (DGX) in Q4 2022, closing a stake of 6,480 shares — an estimated $791K sold.

Chimera Capital Management first reported a position in DGX in Q3 2022 and held it in 1 quarter. The position peaked at $791K in Q3 2022. 879 funds tracked by Wall St. Rank hold DGX as of Q4 2022.

  • Chimera Capital Management reported no remaining Quest Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Chimera Capital Management sold 6,480 Quest Diagnostics shares in Q4 2022, an estimated $791K.
  • Chimera Capital Management first reported a position in Quest Diagnostics in Q3 2022 and held it in 1 quarter.
  • Chimera Capital Management's Quest Diagnostics position peaked at $791K in Q3 2022.
  • 879 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2022.

Based on Chimera Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.